Update on treatment of psoriatic arthritis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue 3, 2012, Pages 167-171

  Mease, Philip ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; APREMILAST; BRODALUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; INTERLEUKIN 17 INHIBITOR; INTERLEUKIN 6 INHIBITOR; IXEKIZUMAB; JANUS KINASE INHIBITOR; METHOTREXATE; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ANEMIA; DACTYLITIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; ENTHESITIS; FIBROMYALGIA; GOLD STANDARD; HEADACHE; HUMAN; HYPERLIPIDEMIA; INFECTION; NAIL DISEASE; NAUSEA; NEOPLASM; NEUTROPENIA; OBESITY; OSTEOARTHRITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY MEDICAL CARE; PSORIATIC ARTHRITIS; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONDYLITIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL AGENTS; HUMANS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84869452760     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Dominguez P, Gladman D, Helliwell P, et al. Development of screening tools to identify psoriatic arthritis. Curr Rheumatol Rep. 2010 Aug;12(4):295-9.
2. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S64-85
3. Helliwell P, Fitzgerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2012 Jul 13. [Epub ahead of print]
4. Helliwell PS, Fitzgerald O, Strand CV, Mease PJ. Composite measures in psoriatic arthritis: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011 Mar;38(3):540-5
5. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010 Jan;69(1):48-53
6. Gossec L, Smolen J, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan;71(1):4-12. Epub 2011 Sep 27
7. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9):1387-94
8. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012 Aug;71(8):1273-7
9. Di Minno M, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity. A prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). 2012 Apr 18. doi: 10.1002/acr.21711. [Epub ahead of print]
10. Di Minno M, Iervolino S, Peluso R, et al. Weight loss and induction of minimal disease activity in psoriatic arthritis patients starting TNF-a blockers treatment. Ann Rheum Dis. 2012 Oct 4;14(5):R211. [Epub ahead of print]
11. Iannone F, Fanizzi R, Scioscia C, et al. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-a therapy. Scand J Rheumatol. 2012 Sep 20. [Epub ahead of print]
12. Mease PJ. Spondyloarthritis: Is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol. 2012 May 2;8(5):251-2
13. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012 Aug;51(8):1368-77. Epub 2012 Feb 17
14. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 Apr;71(4):541-8
15. Mease P, Fleischmann R, Deodhar A, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2012;71:S150
16. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr;60(4):976-86
17. Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GOREVEAL study. Ann Rheum Dis. 2009 Jul;68:S136-7
18. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009 Feb 21;373(9664):633-40
19. McInnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis. 2012 Jun;71:S107
20. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2010 Apr;63(4):939-48
21. Mease P, Genovese M, Gladstein G, et al. Abatacept (ABA) in the treatment of Psoriatic Arthritis (PsA): 12-month results of a phase II study. Arthritis Rheum. 2010 Oct;62:S802
22. Mease P. Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis? J Rheumatol. 2012. [Epub ahead of print]
23. Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011 Mar;70 Suppl 1:i77-84
24. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012 Oct;64(10):3156-67